MPI STANNOUS DIPHOSPHONATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MPI STANNOUS DIPHOSPHONATE (MPI STANNOUS DIPHOSPHONATE).
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
| Metabolism | Stannous diphosphonate is not metabolized; it is eliminated renally as the intact complex. |
| Excretion | Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%). |
| Half-life | Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection. |
| Protein binding | Approximately 20–30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution: 0.3–0.5 L/kg, indicating distribution primarily into the extracellular fluid and bone. |
| Bioavailability | Intravenous: 100% (only route of administration). |
| Onset of Action | Intravenous: Skeletal uptake begins within minutes; optimal imaging is performed 2–4 hours after injection. |
| Duration of Action | The radiopharmaceutical remains bound to bone for several hours, allowing imaging up to 4–6 hours; after 24 hours, minimal activity remains in soft tissues. |
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
| Dosage form | INJECTABLE |
| Renal impairment | No formal recommendations; use caution in severe renal impairment (GFR <30 mL/min) as reduced clearance may increase radiation exposure. |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Weight-based: 0.05-0.1 mg/kg (maximum 4 mg) intravenously, single dose. |
| Geriatric use | No specific dose adjustment; consider age-related renal function decline and monitor accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MPI STANNOUS DIPHOSPHONATE (MPI STANNOUS DIPHOSPHONATE).
| Breastfeeding | Tc-99m MDP is excreted in breast milk. The milk-to-plasma ratio (M/P) is not specifically reported, but the effective half-life in milk is approximately 4-6 hours. Breastfeeding should be interrupted for at least 24-48 hours after administration to minimize infant radiation exposure. Tc-99m decays rapidly (half-life ~6 hours), so milk may be pumped and discarded during this period. |
| Teratogenic Risk | Not formally evaluated in pregnant women. Radiopharmaceuticals like Tc-99m MDP (derived from stannous diphosphonate) cross the placenta. First trimester: risk of fetal radiation exposure (estimated fetal dose ~2-5 mGy for typical 20 mCi Tc-99m MDP administration); theoretical risk of teratogenicity from radiation above background. Second and third trimesters: continued risk of intrauterine radiation exposure, but lower risk of organogenesis effects. No evidence of specific malformations in humans; animal studies not available. Cumulative fetal dose should be kept below 50 mGy. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to stannous diphosphonate or any component of the formulation.","Pregnancy (avoid unless benefit outweighs risks due to radiation exposure).","Use in pediatric patients only if diagnostic yield outweighs radiation risk."]
| Precautions | ["Risk of hypersensitivity reactions including anaphylaxis.","Radiation exposure; ensure proper justification and minimize exposure.","Not for intrathecal administration.","Contaminated products may cause adverse effects."] |
Loading safety data…
| Fetal Monitoring | Before administration: confirm pregnancy status in women of childbearing potential. During: no specific monitoring required for the drug itself; standard vital signs as per institutional protocol. Post-administration: assess for allergic reactions (rare). For Tc-99m MDP, ensure adequate hydration to promote renal clearance and reduce radiation dose to bladder and uterus. |
| Fertility Effects | No specific data on fertility impairment. Radiation exposure from this diagnostic dose (typically <10 mSv) is unlikely to adversely affect fertility. However, high cumulative radiation doses may theoretically impact gonadal function; not reported with standard single administration. |